VALEANT PHARMACEUTICALS INTL I (VRX) Stock Price, Quote, News and Overview
NYSE:VRX - New York Stock Exchange, Inc. - CA91911K1021
VRX Quote, Performance and Key Statistics
23.4
-0.83 (-3.43%)
The current stock price of VRX is 23.4 null. In the past month the price decreased by -12.69%. In the past year, price increased by 35.73%.
About VRX
Company Profile
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.
Company Info
VALEANT PHARMACEUTICALS INTL I
2150 ST. ELZEAR BLVD. WEST
LAVAL A8 H7L 4A8
CEO: Joseph C. Papa
Phone: 514-744-6792
VALEANT PHARMACEUTICALS INTL I / VRX FAQ
What is the stock price of VALEANT PHARMACEUTICALS INTL I today?
The current stock price of VRX is 23.4 null. The price decreased by -3.43% in the last trading session.
What is the ticker symbol for VALEANT PHARMACEUTICALS INTL I stock?
The exchange symbol of VALEANT PHARMACEUTICALS INTL I is VRX and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is VRX stock listed?
VRX stock is listed on the New York Stock Exchange, Inc. exchange.
What is VALEANT PHARMACEUTICALS INTL I worth?
VALEANT PHARMACEUTICALS INTL I (VRX) has a market capitalization of 8.16B null. This makes VRX a Mid Cap stock.
What are the support and resistance levels for VALEANT PHARMACEUTICALS INTL I (VRX) stock?
VALEANT PHARMACEUTICALS INTL I (VRX) has a support level at 23.38 and a resistance level at 26.69. Check the full technical report for a detailed analysis of VRX support and resistance levels.
Should I buy VALEANT PHARMACEUTICALS INTL I (VRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VRX, evaluating the profitability, health, valuation and growth aspects
- VALEANT PHARMACEUTICALS INTL I (VRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VALEANT PHARMACEUTICALS INTL I (VRX) Sales and EPS estimates to see what analysts future expectations are.
- VALEANT PHARMACEUTICALS INTL I (VRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VALEANT PHARMACEUTICALS INTL I (VRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VALEANT PHARMACEUTICALS INTL I (VRX) Stock Chart to make your own analysis
- VALEANT PHARMACEUTICALS INTL I (VRX) Latest news and press-releases to stay up to date.
Does VALEANT PHARMACEUTICALS INTL I (VRX) stock pay dividends?
VRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of VALEANT PHARMACEUTICALS INTL I (VRX)?
The PE ratio for VALEANT PHARMACEUTICALS INTL I (VRX) is 5.91. This is based on the reported non-GAAP earnings per share of 3.96 and the current share price of 23.4 null. Check the full fundamental report for a full analysis of the valuation metrics for VRX.
VRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VRX. When comparing the yearly performance of all stocks, VRX is one of the better performing stocks in the market, outperforming 90.59% of all stocks.
VRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VRX. VRX has a medium profitability rating, but doesn't score so well on its financial health evaluation.
VRX Financial Highlights
Over the last trailing twelve months VRX reported a non-GAAP Earnings per Share(EPS) of 3.96. The EPS decreased by -29.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -10.65% | ||
| ROA | -2.56% | ||
| ROE | -20.27% | ||
| Debt/Equity | 5.59 |